Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05509933
PHASE3
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Sponsor: Henry Ford Health System
View on ClinicalTrials.gov
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2022-11-09
Completion Date
2026-12-30
Last Updated
2025-04-29
Healthy Volunteers
No
Conditions
Interventions
DRUG
Budesonide
budesonide starting day 5 after transplant
Locations (1)
Henry Ford Health System
Detroit, Michigan, United States